MSDC0602 is primarily investigated for its potential therapeutic applications in metabolic disorders and neurodegenerative diseases. It acts as a modulator of mitochondrial function, targeting the mitochondrial pyruvate carrier (MPC), which plays a critical role in cellular energy metabolism. This mechanism makes it a promising candidate for treating type 2 diabetes, as it helps regulate glucose metabolism and insulin sensitivity. Additionally, research suggests its potential in addressing Alzheimer's disease by mitigating mitochondrial dysfunction, which is often linked to neurodegeneration. Its ability to improve metabolic and cellular health has also sparked interest in exploring its use for other conditions, such as non-alcoholic steatohepatitis (NASH) and age-related metabolic decline. Ongoing studies aim to further validate its efficacy and safety in these areas.